Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease.

Key facts

Study ID

NCT00420732

Run by

NewLink Genetics Corporation

People needed

6

Starts

2007-01-01

Expected to finish

2014-12-01

Last updated by the study team

2020-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• histological diagnosis of non-small cell lung cancer. Squamous cell (epidermoid), adenocarcinoma, bronchoalveolar carcinoma and large cell anaplastic lung carcinoma histologies are eligible. Mixed NSCLC/small cell, and variant large and small are not eligible.
• AJCC Stage IIIB(pleural effusion) or Stage IV NSCLC
• Subjects must have been previously treated with only a first line platinum-doublet therapy that may or may not include Avastin(R). Those treated with definitive chemo-radiation with curative or palliative intent or who have received multiple regimens are not eligible.
• Subjects' NSCLC must have responded or remained stable through first line platinum-doublet therapy.
• ECOG Performance Status ≤ 2.
• Serum albumin ≥ 3.0 gm/dL.
• Expected survival ≥ 6 months.
• Hemoglobin ≥ 9.0 g/dl
• Platelets ≥ 100,000 cells/mm3
• ANC ≥ 1500 cells/mm3
• Serum total bilirubin ≤ 2 x ULN, ALT and AST ≤ 2.5 x ULN (≤5 if hepatic metastasis is present).
• Serum creatinine ≤ 1.5 x ULN, or creatinine clearance ≥ 50 ml/min.
• Measurable or non-measurable disease.
• Subjects must have negative serology for HIV prior to entering study.
• Male and female subjects of child bearing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving experimental drug, and for one month after the last immunization.

You may not qualify if…

• Age < 18 years.
• Active CNS metastases or carcinomatous meningitis.
• Subjects' whose NSCLC progressed during/after first line platinum-doublet therapy.
• Subjects having undergone splenectomy.
• Hypercalcemia > 2.9 mmol/L, unresponsive to standard therapy.
• Pregnant or nursing women.
• Other malignancy within the last 5 years, unless the probability of recurrence of the prior malignancy is < 30%. Patient's curatively treated for squamous and basal cell carcinoma of the skin and carcinoma in situ of the uterine cervix (CIN) or subjects with a history of malignant tumor in the past that have been disease free for at least five years are also eligible for this study.
• History of organ transplant.
• Current, active treatment with immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
• Subjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism, are not eligible. Subjects receiving inhaled or topical corticosteroids are eligible.
• Significant or uncontrolled congestive heart failure, myocardial infarction, significant ventricular arrhythmias within the last six months or significant pulmonary dysfunction.
• Active infection or antibiotics within 1-week prior to study, including unexplained fever.
• Autoimmune disease.
• Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study.
• A known allergy to any component of the vaccine.

Where it is running

• Northwestern University — Chicago, Illinois, United States
• Washington University in St. Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.